Stelara Approved in US to Treat Moderate-to-Severe Ulcerative Colitis

Stelara Approved in US to Treat Moderate-to-Severe Ulcerative Colitis
The U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of adults with ulcerative colitis (UC) that is moderately to severely active, Janssen Pharmaceuticals, Stelara’s developer and part of Johnson & Johnson, announced. The FDA’s decision follows the approval by the European Commission in September for the same condition. "Because of the individual nature of ulcerative colitis, what works for one patient may not work for another. That is why it is so critical that our ulcerative colitis patients have many different treatment options available to them," Caren Heller, MD, MBA, chief scientific officer at the Crohn's & Colitis Foundation, said in a press release. "The approval of STELARA is extremely important for patients living with moderate to severe ulcerative colitis. STELARA gives patients another option to, hopefully, induce remission and help manage their disease," Heller added. Stelara is a biologic agent that works by inhibiting the activity of two pro-inflammatory
Subscribe or to access all post and page content.